Standard BioTools (FLB) Financial Statements
4 Followers
Standard BioTools Financial Overview
Standard BioTools's market cap is currently $214.16M. The company's EPS TTM is $-0.23; its P/E ratio is -5.56; Standard BioTools is estimated to report earnings on November 10, 2026, and the estimated EPS forecast is $-0.02. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 85.33M | $ 174.43M | $ 106.34M | $ 97.95M | $ 130.58M |
| Gross Profit | $ 42.54M | $ 84.26M | $ 50.45M | $ 37.05M | $ 69.37M |
| Operating Income | $ -93.31M | $ -175.24M | $ -76.60M | $ -116.20M | $ -67.46M |
| EBITDA | $ -85.70M | $ -118.14M | $ -54.46M | $ -173.57M | $ -44.27M |
| Net Income | $ -74.90M | $ -138.88M | $ -74.66M | $ -190.10M | $ -59.24M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 187.57M | $ 292.87M | $ 114.89M | $ 165.78M | $ 28.45M |
| Total Assets | $ 567.75M | $ 612.34M | $ 323.07M | $ 390.31M | $ 275.21M |
| Total Debt | $ 30.83M | $ 33.00M | $ 98.21M | $ 102.66M | $ 111.65M |
| Net Debt | $ -87.39M | $ -133.73M | $ 46.51M | $ 21.35M | $ 83.20M |
| Total Liabilities | $ 143.46M | $ 140.62M | $ 471.12M | $ 471.78M | $ 180.62M |
| Stockholders' Equity | $ 424.29M | $ 471.72M | $ -148.05M | $ -81.47M | $ 94.60M |
| Cash Flow | |||||
| Free Cash Flow | $ -82.65M | $ -151.81M | $ -46.12M | $ -93.19M | $ -57.33M |
| Operating Cash Flow | $ -74.35M | $ -143.45M | $ -43.29M | $ -89.37M | $ -44.06M |
| Investing Cash Flow | $ 24.77M | $ 363.17M | $ 20.24M | $ -88.13M | $ -11.95M |
| Financing Cash Flow | $ 570.00K | $ -102.62M | $ -6.81M | $ 230.76M | $ 15.96M |
Currency in USD
